According to the news from Zhitong Finance and Economics APP, Huangshan Jiaonang (002817.SZ) released its 2024 interim report. During the reporting period, the company achieved operating income of 235 million yuan, a year-on-year decrease of 7.98%. The net profit attributable to shareholders of the listed company was 29.6824 million yuan, a year-on-year decrease of 21.84%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 27.8476 million yuan, a year-on-year decrease of 18.98%. The basic earnings per share was 0.1 yuan.

During the reporting period, the company closely focused on the development goals set at the beginning of the year, concentrated on its main business, actively responded to changes in the pharmaceutical industry environment, conducted production in accordance with the principle of "standardizing processes, focusing on details, and ensuring results", accelerated innovation in marketing models, strengthened market development efforts, and enhanced internal management and cost control